Related Experiment Video
Updated: Jun 22, 2025
Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
Published on: February 24, 2023
Post COVID-19 Pandemic Increased Detection of Mycoplasma Pneumoniae in Adults Admitted to the Intensive Care
M Goeijenbier1,2, S van der Bie1, D Souverein3
1Department of Intensive Care Medicine, Spaarne Gasthuis, 2035 RC Haarlem, The Netherlands.
Abstract:
Background: Mycoplasma pneumoniae (M. pneumoniae) infections can progress to severe respiratory complications, necessitating intensive care treatment. Recent post COVID-19 pandemic surges underscore the need for timely diagnosis, given potential diagnostic method limitations. Methods: A retrospective case series analysis was conducted on M. pneumonia PCR-positive patients admitted to two Dutch secondary hospitals' ICUs between January 2023 and February 2024. Clinical presentations, treatments, outcomes, and mechanical ventilation data were assessed. Results: Seventeen ICU-admitted patients were identified, with a median age of 44 years, primarily due to hypoxia. Non-invasive ventilation was effective for most, while five required invasive mechanical ventilation. None of the patients required extracorporeal membrane oxygenation. No fatalities occurred. Post-PCR, treatment was adjusted to doxycycline or azithromycin; seven received steroid treatment. Discussion: Increased ICU admissions for M. pneumoniae infection were observed. Diverse clinical and radiological findings emphasize heightened clinical awareness. Early molecular diagnostics and tailored antibiotic regimens are crucial since beta-lactam antibiotics are ineffective. Conclusion: This study highlights the escalating challenge of severe M. pneumoniae infections in ICUs, necessitating a multifaceted approach involving accurate diagnostics, vigilant monitoring, and adaptable treatment strategies for optimal patient outcomes.
Insights
Severe Mycoplasma pneumoniae infections are increasing in ICUs. Early PCR diagnosis and macrolide antibiotics are vital for effective treatment and improved patient outcomes.
Area of Science:
- Infectious Diseases
- Pulmonology
- Critical Care Medicine
Background:
- Mycoplasma pneumoniae infections can cause severe respiratory illness requiring intensive care.
- Post-COVID-19 pandemic surges highlight challenges in timely diagnosis.
- Limitations in current diagnostic methods necessitate improved approaches.
Purpose of the Study:
- To analyze clinical features, treatments, and outcomes of Mycoplasma pneumoniae patients admitted to intensive care units (ICUs).
- To assess the impact of diagnostic delays and treatment strategies on patient recovery.
- To inform clinical awareness and management protocols for severe M. pneumoniae infections.
Main Methods:
- Retrospective case series of M. pneumoniae PCR-positive patients in Dutch ICUs (January 2023 - February 2024).
- Analysis of clinical presentations, ICU management, mechanical ventilation use, and treatment adjustments.
- Evaluation of patient outcomes, including mortality and need for advanced respiratory support.
Main Results:
- Seventeen patients admitted to ICU with M. pneumoniae, median age 44, primarily due to hypoxia.
- Non-invasive ventilation sufficed for most; five required invasive mechanical ventilation.
- No ECMO or fatalities; treatment shifted to doxycycline/azithromycin post-PCR; seven received steroids.
Conclusions:
- Observed increase in ICU admissions for M. pneumoniae infections.
- Diverse clinical presentations require heightened clinical suspicion and early molecular diagnostics.
- Tailored antibiotic therapy (macrolides) is crucial, as beta-lactams are ineffective; vigilant monitoring and adaptable strategies are essential for optimal outcomes.
Related Concept Videos
01:30Pneumonia III: Complications and Assessment
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia II: Pathophysiology
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: